Entries by Thomas Gabrielczyk

Ceres Brain Therapeutics announces €6m financing

Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.

PRAC: Semaglutide linked to rare eye disease?

The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.

DeepLife raises US$10m in Series A financing

Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens Innovation Santé with participation from Beiersdorf Venture Capital, Prunay Group, and existing investors.

,

Membrane target triggers inflammation

Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.